Marketers Should Note These 5 Things From Google Parent Alphabet’s Earnings - WSJ https://t.co/Vmm1HmHhgM
7:36pm January 30th 2017 via Hootsuite
RT @EricTopol: Revealing without revealing...#genomics dx & privacy https://t.co/fYX0HaJcSl nice work @karthikj89 https://t.co/9Ao7H255o
3:28pm January 29th 2017 via Hootsuite
RT @atulbutte: Way to go @UCDavis! The coffee genome has been sequenced, & released to the public! https://t.co/KzHLx8O6Mf
12:56pm January 29th 2017 via Hootsuite
MT @Sara_Reardon: We asked open-access champion @mbeisen about plans to run for US Senate. @SenatorPhD. @Naturenews https://t.co/i7AOv4ThtL
4:25pm January 27th 2017 via Hootsuite
RT @NatureNews: Astronaut twin study results are in, work is some of the most detailed molecular profiling ever done: https://t.co/Ztnnxots…
3:13pm January 27th 2017 via Twitter Web Client
RT @moorejh: In 2017, researchers are making #precisionmedicine a priority https://t.co/viff394jAK
3:12pm January 27th 2017 via Hootsuite
Alexa, Stop Making Life Miserable for Anyone With a Similar Name! - WSJ https://t.co/fwj7cc1CTf
2:02pm January 27th 2017 via Hootsuite
Using humor at the office can boost your status (I'm not kidding!) - WSJ https://t.co/HoRzxluT6n
12:16pm January 27th 2017 via Hootsuite
Health Organizations Urge Senate to Update LDT Oversight Rules | GenomeWeb https://t.co/jHtnw3UG8Y
11:45am January 27th 2017 via Hootsuite
Mice cured of diabetes by cells grown inside rats — are humans next? - The Verge https://t.co/NufyIII6uD
10:05am January 27th 2017 via Hootsuite
First human-pig chimeras created, raising hopes for transplantable organs } StatNews https://t.co/XPewtNeFN7
6:35am January 27th 2017 via Hootsuite
"It will be nearly impossible to raise money for an online ad business in 2017" CB Insights - Digital Media PDF https://t.co/yyFy3lbBFt
9:50pm January 26th 2017 via Hootsuite
Vanishing point: the rise of the invisible computer - an interesting take on Moore's Law limits | The Guardian https://t.co/hwZfIcLS1T
9:24pm January 26th 2017 via Hootsuite
Two Infants Treated with Universal Immune Cells Have Their Cancer Vanish https://t.co/uMapOJlr5m
6:00pm January 26th 2017 via Hootsuite
The DNA Test as Horoscope - The Atlantic https://t.co/JWf16M4DWW
1:48pm January 26th 2017 via Hootsuite
.@JustinKlein1 Glad you found the tweets useful at #PMWC17 - I have to express appreciation to @SeraCare for sponsoring and send me here.
11:51am January 26th 2017 via Hootsuite in reply to JustinKlein1
.@PMWCintl So glad I attended @PMWC17 and that @SeraCare could sponsor avwell-received session. Hope to return next year!
11:48am January 26th 2017 via Hootsuite in reply to PMWCintl
.@helixcode Deanna Church from Personalis said that she’d talk about it in her talk, but I was in one of the other 3 tracks...
11:42am January 26th 2017 via Hootsuite in reply to helixcode
Walcoff: The volume of info w/in the medical community: a concern in public health. How to define risk w/vast amt of data? #PMWC17
8:00pm January 25th 2017 via Twitter Web Client
Heichman: As CDx comes to inf disease, may have a larger public health inpact. Want a high bar for custom antibiotics. #PMWC
7:58pm January 25th 2017 via Twitter Web Client
Walcoff: I've seen tremendous movement (from the FDA) in the past few years; what the challenges are from the things they propose #PMWC17
7:55pm January 25th 2017 via Twitter Web Client
Thomae: Points out that CLIA came out during the Reagan administration. Heichman: Still interest in practical considerations #PMWC17
7:54pm January 25th 2017 via Twitter Web Client
Walcoff: The final guidance is the "in or out of LDT's"; it is harder to get a guidance withdrawn. #PMWC17
7:51pm January 25th 2017 via Twitter Web Client
Walcoff: People at HHS w/IVD guidance. 'This is not binding' but it was treated that way. FDA may not finalize it. #PMWC17
7:50pm January 25th 2017 via Twitter Web Client
FDA holding off on final guidance? Thomae: Currently FDA policy, not heard anything to the contrary. Some drug co's may risk it. #PMWC17
7:48pm January 25th 2017 via Twitter Web Client
Thank you to those who at #PMWC17 came up to introduce themselves! https://t.co/lkWAQRCFg8
7:43pm January 25th 2017 via Hootsuite
Walcoff: You are presumably getting more value with more markers; the gov't goal is to pay less. #PMWC17
7:40pm January 25th 2017 via Twitter Web Client
Thomae: Grail was named that way for a reason; it's going to be a lot of data, a lot of sequencing. Payors all sorting that out. #PMWC17
7:39pm January 25th 2017 via Twitter Web Client
Thomae: CUP is tricky too. And what about databases, knowledge bases? What is the intended use? Hard to explain, how specific. #PMWC17
7:38pm January 25th 2017 via Twitter Web Client
Q:Pan-cancer panels? Thomae: It's tricky; different markers have different significance in cancer. From FFPE to ctDNA, #PMWC17
Thomae: An FDA clearance doesn't mean you get reimbursed; #PMWC17 Heichman: The disconnect can be bad - good test, poorly reimbursed.
7:36pm January 25th 2017 via Twitter Web Client
Walcoff: They did everything right on both sides (FDA, CMS) but the Preventative Services TF: have become more influential #PMWC17
7:34pm January 25th 2017 via Twitter Web Client
Thomae: Exact Sciences went down the path of both FDA and CMS reimbursement simultaneously, and did well as a result. #PMWC17
7:33pm January 25th 2017 via Twitter Web Client
Heichman: Lots of tests are complementary Dx - just not labeled that way. Sometimes related to disease rather than the drug. #PMWC17
7:29pm January 25th 2017 via Twitter Web Client
Thomae: An example would be Foundation Med - part of the process. Can be declared a success. #PMWC17
7:23pm January 25th 2017 via Twitter Web Client
Heichman: PD1 is considered a failure; a nightmare for everyone, no standardization. How not to do this. #PMWC17
7:20pm January 25th 2017 via Twitter Web Client
Heichman: They were approved, but not successful. HER2 is routine, widely adopted, effort to standardize. #PMWC17
Q: Examples of success? Heichman: Two successful ones were Orphan Drug Act ones. Rare disease, zero tests in a year. #PMWC17
7:19pm January 25th 2017 via Twitter Web Client
Heichman: Expense of better drugs, better price with better performance; diagnostics do not enjoy those financials. #PMWC17
7:18pm January 25th 2017 via Twitter Web Client
Heichman: Coming to labs early in the design process; for a high-complexity lab, automation is off-label anyway. User needs first. #PMWC17
7:16pm January 25th 2017 via Twitter Web Client
Thomae: It's always the challenge in Dx - will the lab use it? Will they make their own? A product they actually want? #PMWC17
7:15pm January 25th 2017 via Twitter Web Client
Heichman: There's no balance between FDA-approved kit cost, to what the reimbursement is. Incentive is only desire for compliance. #PMWC17
7:14pm January 25th 2017 via Twitter Web Client
Heichman: Challenge is that a CDx can take a long time, the assay may not be the state-of-the-art. Decision made to go w/LDT instead #PMWC17
7:13pm January 25th 2017 via Twitter Web Client
Walcoff: Reimbursement challenges along with reg uncertainty; but still medicine needed. Ordering tests for a variety of reasons #PMWC17
Thomae: Within Pharma world, balance between technology and the lowest risk. #PMWC17
7:10pm January 25th 2017 via Twitter Web Client
Walcoff: The commercial end-product is always the goal; commercial decisions around the drug drive decisions more than the assay. #PMWC17
Thomae: There is a technology component as well; multiplexed tech, thresholds, LoD for FISH or IHC #PMWC17
7:09pm January 25th 2017 via Twitter Web Client
Walcoff: We continue to be in limbo regarding LDTs: a quality system in-place, can be nerve-wracking for trad LDT providers #PMWC17
7:08pm January 25th 2017 via Twitter Web Client
Walcoff: Not all companies are familiar with the FDA and drug-dev process. (She was at FDA, HHS.) Familiarity counts #PMWC17
Q:Adv for size of Dx co? Heichman:Partner they are comfortable with - can they deliver and on time? What about ROW? #PMWC17
7:06pm January 25th 2017 via Twitter Web Client
